
News|Articles|July 2, 2018
- Pharmaceutical Technology\'s In the Lab eNewsletter-07-03-2018
- Volume 13
- Issue 7
Sciex’s New Mass Spec Technologies Enhance Lab Analytics
Author(s)Pharmaceutical Technology Editors
Sciex’s latest additions to its biopharma portfolio helps to optimize workflow for better analytics in the lab.
Sciex’s latest additions to its biopharma portfolio help to optimize workflow for better analytics in the lab.
According to the company, these products have been optimized for maximal sensitivity, accuracy, and efficiency for scientists using challenging workflows in critical fields without sacrificing robustness or ease of use.
Recent additions to the Sciex biopharma portfolio include:
- OptiFlow Quant Solution, which delivers highly sensitive micro-flow quantitation for peptides. This solution includes the OptiFlow Turbo V Source with M5 MicroLC to deliver micro-flow sensitivity at analytical flow usability, with flexible and user-friendly sample handling.
- Multiple Attribute Methodology (MAM) Workflow for simplified, in-depth liquid chromatography-mass spectrometry characterization and development of biologics. The MAM Workflow provides complete analysis of the product quality profile while minimizing the burden of product-quality attribute monitoring and product purity testing and uses the company’s BioPharmaView 3.0 software.
- the SCIEX OS 1.4 software brings the full package for quantitative and qualitative analysis to the majority of SCIEX instruments. The new operating system also offers complete 21 CFR Part 11 compliance for labs in regulated fields.
- the MPX 2.0 software, which was recently developed for multiplexing liquid chromatography separations within a single mass spectrometry system, saves valuable laboratory time while improving flexibility, according to the company.
The company showcased these innovations at ASMS 2018 on June 3–7, 2018 in San Diego, CA.
Source:
Articles in this issue
about 8 years ago
Dissolution Testing: Keeping It Simpleabout 8 years ago
Improvements Needed for Adventitious Agent Testingabout 8 years ago
Alcami Expands Laboratory Services Programabout 8 years ago
Shimadzu’s New Q-TOF System Enhances Mass Spectrometryabout 8 years ago
Waters’ New UPLC Platform Meets Evolving Chromatography Needsover 8 years ago
Juniper Pharma Services Expands Laboratory Facilitiesover 8 years ago
Micromeritics Acquires Freeman TechnologyRelated to this article

The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.

In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.

Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.

The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.

Jaenisch, Muraru, and Pandey debate whether AI "slop" is infiltrating pharma SOPs and deviation reports and who should catch it first.

The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.

The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
3
PharmTech AI Pulse Check: Fixing AI Slop at the Source
4
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
5

